<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32303497
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1473-4893
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical medicine (London, England)
       </title>
       <isoabbreviation>
        Clin Med (Lond)
       </isoabbreviation>
      </journal>
      <articletitle>
       Chloroquine and COVID-19 - a potential game changer?
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       clinmed.2020-0129
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.7861/clinmed.2020-0129
      </elocationid>
      <abstract>
       <abstracttext>
        The novel coronavirus SARS-CoV-2, causing the disease COVID-19, first emerged in Wuhan, China in December 2019 and has now spread to 203 countries or territories, infected over 2 million people and caused over 133,000 deaths. There is an urgent need for specific treatments. One potential treatment is chloroquine and its derivatives, including hydroxychloroquine, which have both antiviral and anti-inflammatory effects. These compounds are effective against SARS-CoV-2
        <i>
         in vitro
        </i>
        , but
        <i>
         in vivo
        </i>
        data are lacking. Although some encouraging outcomes have been reported, and these results have been received enthusiastically, we recommend careful and critical evaluation of current evidence only when all methods and data are available for peer review. Chloroquine is safe and cheap. However, further evidence from coordinated multicentre trials is required before it can be confidently said whether it is effective against the current pandemic.
       </abstracttext>
       <copyrightinformation>
        Â© Royal College of Physicians 2020. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sturrock
        </lastname>
        <forename>
         Beattie Rh
        </forename>
        <initials>
         BR
        </initials>
        <affiliationinfo>
         <affiliation>
          Brighton and Sussex Medical School, Brighton UK and Royal Sussex County Hospital, Brighton, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chevassut
        </lastname>
        <forename>
         Timothy Jt
        </forename>
        <initials>
         TJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Brighton and Sussex Medical School, Brighton UK and consultant haematologist, Royal Sussex County Hospital, Brighton, UK t.chevassut@bsms.ac.uk.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Clin Med (Lond)
      </medlineta>
      <nlmuniqueid>
       101092853
      </nlmuniqueid>
      <issnlinking>
       1470-2118
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-Cov-2
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32303497
      </articleid>
      <articleid idtype="pii">
       clinmed.2020-0129
      </articleid>
      <articleid idtype="doi">
       10.7861/clinmed.2020-0129
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32302411
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1532-6535
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical pharmacology and therapeutics
       </title>
       <isoabbreviation>
        Clin. Pharmacol. Ther.
       </isoabbreviation>
      </journal>
      <articletitle>
       Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/cpt.1857
      </elocationid>
      <abstract>
       <abstracttext>
        Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. It is primarily used for the treatment of respiratory, enteric, and genitourinary bacterial infections. AZ is not approved for the treatment of viral infections, and there is no well-controlled, prospective, randomized clinical evidence to support AZ therapy in COVID-19 (Coronavirus Infectious Disease-2019). Nevertheless, there are anecdotal reports that some hospitals have begun to include AZ in combination with hydroxychloroquine (HCQ) or chloroquine (CQ) for treatment of COVID-19. It is essential that the clinical pharmacology (CP) characteristics of AZ be considered in planning and conducting clinical trials of AZ alone or in combination with other agents, to ensure safe study conduct and to increase the probability of achieving definitive answers regarding efficacy of AZ in the treatment of COVID-19. The safety profile of AZ used as an antibacterial agent is well-established.(1) This work assesses published in vitro and clinical evidence for AZ as an agent with antiviral properties. It also provides basic CP information relevant for planning and initiating COVID-19 clinical studies with AZ, summarizes safety data from healthy volunteer studies, and safety and efficacy from Phase 2 and Phase 2/3 studies in patients with uncomplicated malaria, including a Phase 2/3 study in pediatric patients following administration of AZ and CQ in combination. This paper may also serve to facilitate the consideration and use of a priori-defined control groups for future research.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Damle
        </lastname>
        <forename>
         Bharat
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, New York, NY, 10017, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vourvahis
        </lastname>
        <forename>
         Manoli
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, New York, NY, 10017, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Erjian
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, 10555 Science Center Dr, San Diego, CA, 92121, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Leaney
        </lastname>
        <forename>
         Joanne
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Corrigan
        </lastname>
        <forename>
         Brian
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, 445 Eastern Point Road, Groton, CT, 06340, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Clin Pharmacol Ther
      </medlineta>
      <nlmuniqueid>
       0372741
      </nlmuniqueid>
      <issnlinking>
       0009-9236
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Azithromycin
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Pharmacokinetics
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Safety
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32302411
      </articleid>
      <articleid idtype="doi">
       10.1002/cpt.1857
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32301155
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1600-6143
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
       </title>
       <isoabbreviation>
        Am. J. Transplant.
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19 in solid organ transplant recipients: a single-center case series from Spain.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1111/ajt.15929
      </elocationid>
      <abstract>
       <abstracttext>
        The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 Â± 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-Î² (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         FernÃ¡ndez-Ruiz
        </lastname>
        <forename>
         Mario
        </forename>
        <initials>
         M
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-0315-8001
        </identifier>
        <affiliationinfo>
         <affiliation>
          Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         AndrÃ©s
        </lastname>
        <forename>
         Amado
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-0238-1364
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Nephrology, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Loinaz
        </lastname>
        <forename>
         Carmelo
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of General Surgery, Digestive Tract and Abdominal Organ Transplantation, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Delgado
        </lastname>
        <forename>
         Juan F
        </forename>
        <initials>
         JF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          CIBER de Enfermedades Cardiovasculares (CIBERCV), Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         LÃ³pez-Medrano
        </lastname>
        <forename>
         Francisco
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         San Juan
        </lastname>
        <forename>
         Rafael
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         GonzÃ¡lez
        </lastname>
        <forename>
         Esther
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Nephrology, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Polanco
        </lastname>
        <forename>
         Natalia
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Nephrology, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Folgueira
        </lastname>
        <forename>
         MarÃ­a Dolores
        </forename>
        <initials>
         MD
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lalueza
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lumbreras
        </lastname>
        <forename>
         Carlos
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aguado
        </lastname>
        <forename>
         JosÃ© MarÃ­a
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de InvestigaciÃ³n Sanitaria Hospital ", 12 de Octubre" (imas12), Madrid, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Am J Transplant
      </medlineta>
      <nlmuniqueid>
       100968638
      </nlmuniqueid>
      <issnlinking>
       1600-6135
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       outcome
      </keyword>
      <keyword majortopicyn="N">
       solid organ transplantation
      </keyword>
      <keyword majortopicyn="N">
       treatment
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32301155
      </articleid>
      <articleid idtype="doi">
       10.1111/ajt.15929
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32299202
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1303-6165
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Turkish journal of medical sciences
       </title>
       <isoabbreviation>
        Turk J Med Sci
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.3906/sag-2004-168
      </elocationid>
      <abstract>
       <abstracttext>
        In the Wuhan province of China, in December 2019, the novel Coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines ?cytokine storm? leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe disease of COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe lung disease. In this review, to better gain information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tufan
        </lastname>
        <forename>
         Abdurrahman
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         AvanoÄlu GÃ¼ler
        </lastname>
        <forename>
         Aslihan
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Matucci-Cerinic
        </lastname>
        <forename>
         Marco
        </forename>
        <initials>
         M
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Turkey
      </country>
      <medlineta>
       Turk J Med Sci
      </medlineta>
      <nlmuniqueid>
       9441758
      </nlmuniqueid>
      <issnlinking>
       1300-0144
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       anti-inflammatory
      </keyword>
      <keyword majortopicyn="N">
       cytokine storm
      </keyword>
      <keyword majortopicyn="N">
       inflammation
      </keyword>
      <keyword majortopicyn="N">
       rheumatology
      </keyword>
      <keyword majortopicyn="N">
       treatment
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32299202
      </articleid>
      <articleid idtype="doi">
       10.3906/sag-2004-168
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32297571
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1875-533X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Current medicinal chemistry
       </title>
       <isoabbreviation>
        Curr. Med. Chem.
       </isoabbreviation>
      </journal>
      <articletitle>
       SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.2174/0929867327666200416131117
      </elocationid>
      <abstract>
       <abstracttext>
        Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to find other more specific antiviral strategies.
       </abstracttext>
       <copyrightinformation>
        CopyrightÂ© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Costanzo
        </lastname>
        <forename>
         Michele
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         De Giglio
        </lastname>
        <forename>
         Maria Anna Rachele
        </forename>
        <initials>
         MAR
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Roviello
        </lastname>
        <forename>
         Giovanni Nicola
        </forename>
        <initials>
         GN
        </initials>
        <affiliationinfo>
         <affiliation>
          Istituto di Biostrutture e Bioimmagini IBB - CNR; Via Mezzocannone 16, I80134 Naples. Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United Arab Emirates
      </country>
      <medlineta>
       Curr Med Chem
      </medlineta>
      <nlmuniqueid>
       9440157
      </nlmuniqueid>
      <issnlinking>
       0929-8673
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       SARS CoV-2
      </keyword>
      <keyword majortopicyn="N">
       antiviral drugs
      </keyword>
      <keyword majortopicyn="N">
       favirapivir
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       lopinavir
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
      <keyword majortopicyn="N">
       ritonavir.
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        13
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        04
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32297571
      </articleid>
      <articleid idtype="pii">
       CMC-EPUB-105865
      </articleid>
      <articleid idtype="doi">
       10.2174/0929867327666200416131117
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32295814
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1469-0756
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Postgraduate medical journal
       </title>
       <isoabbreviation>
        Postgrad Med J
       </isoabbreviation>
      </journal>
      <articletitle>
       Hydroxychloroquine and covid-19.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       postgradmedj-2020-137785
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1136/postgradmedj-2020-137785
      </elocationid>
      <abstract>
       <abstracttext>
        Hydroxychloroquine and chloroquine are medications that have been used for a long time. Their most common use is for the treatment and prophylaxis of malaria. However, these antimalarial drugs are known to also have anti-inflammatory and antiviral effects and are used for several chronic diseases such as systemic lupus erythematosus with low adverse effects. The antiviral action of hydroxychloroquine and chloroquine has been a point of interest to different researchers due to its mechanism of action. Several in vitro studies have proven their effectiveness on severe acute respiratory syndrome virus and currently both in vitro and in vivo studies have been conducted on 2019 novel coronavirus (covid-19). The purpose of this article is to review the history and mechanism of actions of these drugs and the potential use they can have on the current covid-19 pandemic.
       </abstracttext>
       <copyrightinformation>
        Â© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sinha
        </lastname>
        <forename>
         Neeraj
        </forename>
        <initials>
         N
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-6028-3271
        </identifier>
        <affiliationinfo>
         <affiliation>
          Pulmonary Transplant, University of Miami Miller School of Medicine, Miami, Florida, USA nsinhamd@yahoo.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Balayla
        </lastname>
        <forename>
         Galit
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          General Medicine, Central University of Venezuela, Caracas, Venezuela.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Postgrad Med J
      </medlineta>
      <nlmuniqueid>
       0234135
      </nlmuniqueid>
      <issnlinking>
       0032-5473
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       thoracic medicine
      </keyword>
     </keywordlist>
     <coistatement>
      Competing interests: None declared.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32295814
      </articleid>
      <articleid idtype="pii">
       postgradmedj-2020-137785
      </articleid>
      <articleid idtype="doi">
       10.1136/postgradmedj-2020-137785
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32293710
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1096-9071
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of medical virology
       </title>
       <isoabbreviation>
        J. Med. Virol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/jmv.25887
      </elocationid>
      <abstract>
       <abstracttext>
        COVID-19 infection and its severity can be explained by the concentration of glycosylated SARS- CoV-2 viral particles in the lung epithelium, the concentration of glycosylated angiotensin converting enzyme receptor 2 (ACE2) in the lung epithelium, and the degree and control of the pulmonary immune response to the SARS-CoV-2 spike protein at approximately day 8-10 after symptom onset, which may be related to both. Binding of ACE2 by SARS-CoV-2 in COVID-19 also suggests that prolonged uncontrolled hyperglycemia, and not just a history of diabetes mellitus, may be important in the pathogenesis of the disease. It is tempting to consider that the same mechanism acts in COVID-19 as in SARS, where an overactive macrophage M1 inflammatory response, as neutralizing antibodies to the SARS-CoV- 2 spike protein form at day 7-10, results in acute respiratory distress syndrome (ARDS) in susceptible patients. It is also allows consideration of agents, such as hydroxychloroquine, which may interfere with this overly brisk macrophage inflammatory response and perhaps influence the course of the disease, in particular those that blunt but do not completely abrogate the M1 to M2 balance in macrophage polarization, as well as viral load, which in SARS appears to be temporally related to the onset of ARDS. This article is protected by copyright. All rights reserved.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Brufsky
        </lastname>
        <forename>
         Adam
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-8080-7960
        </identifier>
        <affiliationinfo>
         <affiliation>
          UPMC Hillman Cancer Center, Magee Women's Hospital, University of Pittsburgh School of Medicine, Suite 4628, 300 Halket Street, Pittsburgh, PA, 15213.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Med Virol
      </medlineta>
      <nlmuniqueid>
       7705876
      </nlmuniqueid>
      <issnlinking>
       0146-6615
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       SARS coronavirus
      </keyword>
      <keyword majortopicyn="N">
       antibody-mediated cell-mediated cytotoxicity
      </keyword>
      <keyword majortopicyn="N">
       antiviral agents
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32293710
      </articleid>
      <articleid idtype="doi">
       10.1002/jmv.25887
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292909
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2590-0986
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Medicine in drug discovery
       </title>
       <isoabbreviation>
        Med Drug Discov
       </isoabbreviation>
      </journal>
      <articletitle>
       Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
      </articletitle>
      <pagination>
       <medlinepgn>
        100037
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.medidd.2020.100037
      </elocationid>
      <abstract>
       <abstracttext>
        The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
       </abstracttext>
       <copyrightinformation>
        Â© 2020 Published by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Liao
        </lastname>
        <forename>
         Jiayu
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Way
        </lastname>
        <forename>
         George
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Madahar
        </lastname>
        <forename>
         Vipul
        </forename>
        <initials>
         V
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Med Drug Discov
      </medlineta>
      <nlmuniqueid>
       101765689
      </nlmuniqueid>
      <issnlinking>
       2590-0986
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Host factor
      </keyword>
      <keyword majortopicyn="N">
       Influenza virus
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Therapeutics
      </keyword>
      <keyword majortopicyn="N">
       drug discovery
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292909
      </articleid>
      <articleid idtype="doi">
       10.1016/j.medidd.2020.100037
      </articleid>
      <articleid idtype="pii">
       S2590-0986(20)30024-5
      </articleid>
      <articleid idtype="pii">
       100037
      </articleid>
      <articleid idtype="pmc">
       PMC7153514
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2012 Jan;86(2):642-54
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22072786
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16801417
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Opin Pharmacol. 2016 Oct;30:106-115
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27570127
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        RNA Biol. 2011 Mar-Apr;8(2):270-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21593585
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Mol Biosyst. 2012 Jun;8(6):1723-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22466055
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 1997 Dec 5;278(5344):1803-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9388184
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18625765
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Genet. 2008 Apr;9(4):267-76
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18319742
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2009 Mar 11;301(10):1034-41
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19255110
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2010 Mar 05;7:53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20202225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Microb Drug Resist. 2017 Mar;23(2):253-260
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27203354
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virology. 2014 Aug;462-463:135-48
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24971706
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur J Pharmacol. 2017 Aug 15;809:178-190
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28533172
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Oct;110:94-103
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25108173
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1993 May 1;90(9):4171-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8387212
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32290293
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1422-0067
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         21
        </volume>
        <issue>
         7
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of molecular sciences
       </title>
       <isoabbreviation>
        Int J Mol Sci
       </isoabbreviation>
      </journal>
      <articletitle>
       A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       E2657
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.3390/ijms21072657
      </elocationid>
      <abstract>
       <abstracttext>
        The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including
        <i>
         favipiravir
        </i>
        , a broad-spectrum antiviral drug that interferes with the viral replication, and
        <i>
         hydroxychloroquine
        </i>
        , the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tu
        </lastname>
        <forename>
         Yung-Fang
        </forename>
        <initials>
         YF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chien
        </lastname>
        <forename>
         Chian-Shiu
        </forename>
        <initials>
         CS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yarmishyn
        </lastname>
        <forename>
         Aliaksandr A
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Ying
        </forename>
        <initials>
         YY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luo
        </lastname>
        <forename>
         Yung-Hung
        </forename>
        <initials>
         YH
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Tsung
        </forename>
        <initials>
         YT
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lai
        </lastname>
        <forename>
         Wei-Yi
        </forename>
        <initials>
         WY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         De-Ming
        </forename>
        <initials>
         DM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chou
        </lastname>
        <forename>
         Shih-Jie
        </forename>
        <initials>
         SJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yi-Ping
        </forename>
        <initials>
         YP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Mong-Lien
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chiou
        </lastname>
        <forename>
         Shih-Hwa
        </forename>
        <initials>
         SH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Genomic Research Center, Academia Sinica, Taipei 11529, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Int J Mol Sci
      </medlineta>
      <nlmuniqueid>
       101092791
      </nlmuniqueid>
      <issnlinking>
       1422-0067
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D007155">
        Immunologic Factors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705128">
       COVID-19 serotherapy
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000235">
        genetics
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016679">
        Genome, Viral
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007116">
        Immunization, Passive
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007155">
        Immunologic Factors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014765">
        Viral Vaccines
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       clinical trials
      </keyword>
      <keyword majortopicyn="N">
       immunotherapy
      </keyword>
      <keyword majortopicyn="N">
       pneumonia
      </keyword>
      <keyword majortopicyn="N">
       replicase
      </keyword>
      <keyword majortopicyn="N">
       vaccine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32290293
      </articleid>
      <articleid idtype="pii">
       ijms21072657
      </articleid>
      <articleid idtype="doi">
       10.3390/ijms21072657
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32285930
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1532-6535
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical pharmacology and therapeutics
       </title>
       <isoabbreviation>
        Clin. Pharmacol. Ther.
       </isoabbreviation>
      </journal>
      <articletitle>
       Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/cpt.1856
      </elocationid>
      <abstract>
       <abstracttext>
        Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus Disease of 2019 (COVID-19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment. The data sources included were 1) longitudinal clinical, pharmacokinetic, and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n=116), 2) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, 3) a population pharmacokinetic model of HCQ and 4) a model relating chloroquine pharmacokinetics to QTc prolongation. A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation. SARS-CoV-2 viral decline was associated with HCQ pharmacokinetics (p&lt;0.001). The extrapolated patient EC
        <sub>
         50
        </sub>
        was 4.7 ÂµM, comparable to the reported in vitro EC
        <sub>
         50
        </sub>
        's. HCQ doses &gt; 400 mg BID for â¥5 days were predicted to rapidly decrease viral loads, reduce the proportion of patients with detectable SARS-CoV-2 infection, and shorten treatment courses, compared to lower dose (â¤400 mg daily) regimens. However, HCQ doses &gt;600 mg BID were also predicted to prolong QTc intervals. This prolongation may have clinical implications warranting further safety assessment. Due to COVID-19's variable natural history, lower dose HCQ regimens may be indistinguishable from controls. Evaluation of higher HCQ doses is needed to ensure adequate safety and efficacy.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Garcia-Cremades
        </lastname>
        <forename>
         Maria
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Solans
        </lastname>
        <forename>
         Belen P
        </forename>
        <initials>
         BP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hughes
        </lastname>
        <forename>
         Emma
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ernest
        </lastname>
        <forename>
         Jacqueline P
        </forename>
        <initials>
         JP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wallender
        </lastname>
        <forename>
         Erika
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of California, San Francisco, California, 94110, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aweeka
        </lastname>
        <forename>
         Francesca
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of California, San Francisco, California, 94110, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luetkemeyer
        </lastname>
        <forename>
         Annie
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Deprtment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Savic
        </lastname>
        <forename>
         Radojka M
        </forename>
        <initials>
         RM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Clin Pharmacol Ther
      </medlineta>
      <nlmuniqueid>
       0372741
      </nlmuniqueid>
      <issnlinking>
       0009-9236
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Infectious Disease
      </keyword>
      <keyword majortopicyn="N">
       Pharmacokinetics-pharmacodynamics
      </keyword>
      <keyword majortopicyn="N">
       Pharmacometrics
      </keyword>
      <keyword majortopicyn="N">
       Translational pharmacokinetics-pharmacodynamics
      </keyword>
      <keyword majortopicyn="N">
       Viral dynamics
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32285930
      </articleid>
      <articleid idtype="doi">
       10.1002/cpt.1856
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32284951
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2328-8957
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
        </pubdate>
       </journalissue>
       <title>
        Open forum infectious diseases
       </title>
       <isoabbreviation>
        Open Forum Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
      </articletitle>
      <pagination>
       <medlinepgn>
        ofaa105
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/ofid/ofaa105
      </elocationid>
      <abstract>
       <abstracttext>
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
       </abstracttext>
       <copyrightinformation>
        Â© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         McCreary
        </lastname>
        <forename>
         Erin K
        </forename>
        <initials>
         EK
        </initials>
        <identifier source="ORCID">
         0000-0001-6705-2225
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pogue
        </lastname>
        <forename>
         Jason M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Open Forum Infect Dis
      </medlineta>
      <nlmuniqueid>
       101637045
      </nlmuniqueid>
      <issnlinking>
       2328-8957
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       lopinavir/ritonavir
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        18
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32284951
      </articleid>
      <articleid idtype="doi">
       10.1093/ofid/ofaa105
      </articleid>
      <articleid idtype="pii">
       ofaa105
      </articleid>
      <articleid idtype="pmc">
       PMC7144823
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2019 Nov 13;69(11):1903-1911
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30753384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Pharmacokinet. 1993 Nov;25(5):392-407
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7904547
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29161116
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2004 Dec;31(4):304-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15494274
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hong Kong Med J. 2003 Dec;9(6):399-406
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14660806
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Mar;84(5):2511-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20032190
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2003 Jun 4;289(21):2801-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12734147
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):64-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32037389
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2020 Mar 5;177:104762
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147496
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2020 Jan 3;21(1):8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31900204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect. 2005 Aug;51(2):98-102
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16038758
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2019 Sep;47(9):e735-e743
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31162191
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 3;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125362
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2015 Dec 15;212(12):1904-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26198719
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 29;395(10225):683-684
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32122468
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2017 Jun 28;9(396):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28659436
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Med. 2006 Sep;3(9):e343
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16968120
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1986-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12682352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Oncologist. 2018 Aug;23(8):943-947
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29622697
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):72-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32074550
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):e30-e31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32032529
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Rev Clin Immunol. 2019 Aug;15(8):813-822
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31219357
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA Intern Med. 2020 Mar 13;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167524
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Korean Med Sci. 2020 Feb 17;35(6):e79
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32056407
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2017 Mar 9;60(5):1648-1661
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28124907
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Life Sci. 2020 May 1;248:117477
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32119961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Jul;14(7):609-18
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24852376
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mBio. 2018 Mar 6;9(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29511076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Public Health. 2016 May-Jun;9(3):227-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27095301
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect Dis. 2017 Jan 15;215(2):171-174
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28073857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        ACS Infect Dis. 2020 Mar 10;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125140
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21876444
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2018 Aug 1;67(4):533-540
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29481659
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2019 Dec 12;381(24):2293-2303
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31774950
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2020 Apr 10;295(15):4773-4779
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32094225
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2020 Apr;20(4):398-400
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32113510
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31925415
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 May;92(5):461-463
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32073161
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ther Drug Monit. 2011 Oct;33(5):573-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21912331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2020 Jan 10;11(1):222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31924756
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Emerg Infect Dis. 2004 Apr;10(4):581-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15200845
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30592986
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18852458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841269
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 4;:105932
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32145363
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2016 Jul 30;388(10043):498-503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27209148
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2018 Feb;150:155-163
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29289665
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2006 May 4;49(9):2845-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16640347
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Infect Control Hosp Epidemiol. 2020 Mar 13;:1-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167442
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chest. 2006 Jun;129(6):1441-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16778260
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32283236
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1097-6787
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of the American Academy of Dermatology
       </title>
       <isoabbreviation>
        J. Am. Acad. Dermatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Does Hydroxychloroquine Combat COVID-19? A Timeline of Evidence.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0190-9622(20)30607-1
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.jaad.2020.04.031
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alia
        </lastname>
        <forename>
         Erisa
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          University of CT Dermatology Department.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Grant-Kels
        </lastname>
        <forename>
         Jane M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          University of CT Dermatology Department. Electronic address: grant@uchc.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Am Acad Dermatol
      </medlineta>
      <nlmuniqueid>
       7907132
      </nlmuniqueid>
      <issnlinking>
       0190-9622
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
      <keyword majortopicyn="N">
       Severe Acute Respiratory Syndrome Coronavirus 2 viral infection
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       worried well
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32283236
      </articleid>
      <articleid idtype="pii">
       S0190-9622(20)30607-1
      </articleid>
      <articleid idtype="doi">
       10.1016/j.jaad.2020.04.031
      </articleid>
      <articleid idtype="pmc">
       PMC7151328
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282502
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1533-4023
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          02
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of cardiovascular pharmacology
       </title>
       <isoabbreviation>
        J. Cardiovasc. Pharmacol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1097/FJC.0000000000000836
      </elocationid>
      <abstract>
       <abstracttext>
        A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Dixon
        </lastname>
        <forename>
         Dave L
        </forename>
        <initials>
         DL
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Van Tassell
        </lastname>
        <forename>
         Benjamin W
        </forename>
        <initials>
         BW
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         VecchiÃ©
        </lastname>
        <forename>
         Alessandra
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bonaventura
        </lastname>
        <forename>
         Aldo
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Talasaz
        </lastname>
        <forename>
         Azita
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Tehran Heart Center, Tehran Province, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kakavand
        </lastname>
        <forename>
         Hesam
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Tehran Heart Center, Tehran Province, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         D'Ascenzo
        </lastname>
        <forename>
         Fabrizio
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Department of Medical Science.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Perciaccante
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University Health Agency Giuliano Isontina, 'San Giovanni di Dio' Hospital, Gorizia, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Castagno
        </lastname>
        <forename>
         Davide
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ammirati
        </lastname>
        <forename>
         Enrico
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Niguarda Hospital, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Biondi-Zoccai
        </lastname>
        <forename>
         Giuseppe
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medico-Surgical Sciences and Biotechnologies Sapienza', University of Rome, Rome, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Mediterranea Cardiocentro, Napoli, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Stevens
        </lastname>
        <forename>
         Michael
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Abbate
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Cardiovasc Pharmacol
      </medlineta>
      <nlmuniqueid>
       7902492
      </nlmuniqueid>
      <issnlinking>
       0160-2446
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282502
      </articleid>
      <articleid idtype="doi">
       10.1097/FJC.0000000000000836
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281583
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1881-7823
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Bioscience trends
       </title>
       <isoabbreviation>
        Biosci Trends
       </isoabbreviation>
      </journal>
      <articletitle>
       Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.5582/bst.2020.03072
      </elocationid>
      <abstract>
       <abstracttext>
        Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gao
        </lastname>
        <forename>
         Jianjun
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Shasha
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Japan
      </country>
      <medlineta>
       Biosci Trends
      </medlineta>
      <nlmuniqueid>
       101502754
      </nlmuniqueid>
      <issnlinking>
       1881-7815
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281583
      </articleid>
      <articleid idtype="doi">
       10.5582/bst.2020.03072
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281481
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1521-6950
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          12
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of toxicology and environmental health. Part B, Critical reviews
       </title>
       <isoabbreviation>
        J Toxicol Environ Health B Crit Rev
       </isoabbreviation>
      </journal>
      <articletitle>
       Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
      </articletitle>
      <pagination>
       <medlinepgn>
        1-5
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1080/10937404.2020.1752340
      </elocationid>
      <abstract>
       <abstracttext>
        As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested
        <i>
         in vivo
        </i>
        and
        <i>
         in vitro
        </i>
        for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Pereira
        </lastname>
        <forename>
         Boscolli Barbosa
        </forename>
        <initials>
         BB
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-2633-9067
        </identifier>
        <affiliationinfo>
         <affiliation>
          Institute of Geography, Department of Environmental Health, Federal University of UberlÃ¢ndia, Santa MÃ´nica Campus, UberlÃ¢ndia, Brazil.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Biotechnology, Department of Genetics and Biochemistry, Federal University of UberlÃ¢ndia, Umuarama Campus, UberlÃ¢ndia, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        12
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       J Toxicol Environ Health B Crit Rev
      </medlineta>
      <nlmuniqueid>
       9802627
      </nlmuniqueid>
      <issnlinking>
       1093-7404
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Toxicology
      </keyword>
      <keyword majortopicyn="N">
       health care
      </keyword>
      <keyword majortopicyn="N">
       public health
      </keyword>
      <keyword majortopicyn="N">
       retinopathy
      </keyword>
      <keyword majortopicyn="N">
       screening
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281481
      </articleid>
      <articleid idtype="doi">
       10.1080/10937404.2020.1752340
      </articleid>
      <articleid idtype="pmc">
       PMC7157945
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Can J Cardiol. 2014 Dec;30(12):1706-15
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25475472
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Des Devel Ther. 2018 Jun 11;12:1685-1695
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29928112
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Discov. 2020 Mar 18;6:16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32194981
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Med Res Opin. 2015 May;31(5):1009-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25734693
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Toxicol Environ Health B Crit Rev. 2020;23(1):27-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31746269
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Dermatol Ther. 2007 Jul-Aug;20(4):160-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17970883
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Rheumatol. 2018 Dec;14(12):693-703
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30401979
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ophthalmology. 2016 Jun;123(6):1386-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26992838
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Drug Investig. 2018 Aug;38(8):653-671
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29737455
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Joint Bone Spine. 2019 Jan;86(1):13-19
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30243782
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ophthalmology. 2003 Jul;110(7):1321-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12867385
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Environ Mol Mutagen. 2001;38(1):69-79
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11473390
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28596841
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Saf. 2018 Oct;41(10):919-931
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29858838
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ophthalmology. 2015 Jan;122(1):110-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25182842
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hong Kong Med J. 2006 Aug;12(4):294-304
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16912357
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arthritis Care Res (Hoboken). 2010 Jun;62(6):775-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20535788
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ophthalmology. 2002 Jul;109(7):1377-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12093666
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2020 Mar 5;177:104762
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147496
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arq Bras Oftalmol. 2019 Jan-Feb;82(1):12-17
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30403262
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Rheumatol. 2000 Dec;27(12):2927-31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11128688
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Inflammopharmacology. 2015 Oct;23(5):231-69
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26246395
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA Ophthalmol. 2014 Dec;132(12):1453-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25275721
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-85-95
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25365095
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Mar 26;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32219882
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281213
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1756-185X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of rheumatic diseases
       </title>
       <isoabbreviation>
        Int J Rheum Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1111/1756-185X.13842
      </elocationid>
      <abstract>
       <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
        The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        A total of 45 articles were screened and five (three in vitro pre-clinical studies and two clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
        Although pre-clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Shah
        </lastname>
        <forename>
         Sanket
        </forename>
        <initials>
         S
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-3224-1151
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology, JIPMER, Puducherry, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Das
        </lastname>
        <forename>
         Saibal
        </forename>
        <initials>
         S
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-3153-4166
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacology, JIPMER, Puducherry, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jain
        </lastname>
        <forename>
         Avinash
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-3207-4509
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, MGMC&amp;H, Jaipur, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, SGPGIMS, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Negi
        </lastname>
        <forename>
         Vir Singh
        </forename>
        <initials>
         VS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology, JIPMER, Puducherry, India.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Int J Rheum Dis
      </medlineta>
      <nlmuniqueid>
       101474930
      </nlmuniqueid>
      <issnlinking>
       1756-1841
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Prevention
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       high-risk
      </keyword>
      <keyword majortopicyn="N">
       hydroxychloroquine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281213
      </articleid>
      <articleid idtype="doi">
       10.1111/1756-185X.13842
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281114
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1875-9114
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Pharmacotherapy
       </title>
       <isoabbreviation>
        Pharmacotherapy
       </isoabbreviation>
      </journal>
      <articletitle>
       Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/phar.2403
      </elocationid>
      <abstract>
       <abstracttext>
        A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year-old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID-19) symptoms, including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 PCR result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and was able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Hillaker
        </lastname>
        <forename>
         Emily
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Family Practice Education, Mercy Health Saint Mary's Grand Rapids, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Belfer
        </lastname>
        <forename>
         Julie J
        </forename>
        <initials>
         JJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Services, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bondici
        </lastname>
        <forename>
         Anamaria
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Murad
        </lastname>
        <forename>
         Hani
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Critical Care, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dumkow
        </lastname>
        <forename>
         Lisa E
        </forename>
        <initials>
         LE
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Services, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D002363">
        Case Reports
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Pharmacotherapy
      </medlineta>
      <nlmuniqueid>
       8111305
      </nlmuniqueid>
      <issnlinking>
       0277-0008
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       pneumonia
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
      <keyword majortopicyn="N">
       viral pneumonia
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281114
      </articleid>
      <articleid idtype="doi">
       10.1002/phar.2403
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32279418
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       12
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1399-3062
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          12
         </day>
        </pubdate>
       </journalissue>
       <title>
        Transplant infectious disease : an official journal of the Transplantation Society
       </title>
       <isoabbreviation>
        Transpl Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1111/tid.13286
      </elocationid>
      <abstract>
       <abstracttext>
        During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Bartiromo
        </lastname>
        <forename>
         MarilÃ¹
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Nephrology Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Borchi
        </lastname>
        <forename>
         Beatrice
        </forename>
        <initials>
         B
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4063-5225
        </identifier>
        <affiliationinfo>
         <affiliation>
          Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Botta
        </lastname>
        <forename>
         Annarita
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-9033-1211
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         BagalÃ 
        </lastname>
        <forename>
         Alfredo
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lugli
        </lastname>
        <forename>
         Gianmarco
        </forename>
        <initials>
         G
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-6626-3258
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tilli
        </lastname>
        <forename>
         Marta
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cavallo
        </lastname>
        <forename>
         Annalisa
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xhaferi
        </lastname>
        <forename>
         Brunilda
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Nephrology Unit, University of Milan-Bicocca, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         CutruzzulÃ 
        </lastname>
        <forename>
         Roberta
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Nephrology Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vaglio
        </lastname>
        <forename>
         Augusto
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biomedical, Experimental and clinical Sciences "Mario Serio", University of Florence, Nephrology and Dialysis Unit, Meyer Children's Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bresci
        </lastname>
        <forename>
         Silvia
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Larti
        </lastname>
        <forename>
         Aida
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Nephrology Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bartoloni
        </lastname>
        <forename>
         Alessandro
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cirami
        </lastname>
        <forename>
         Calogero
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Nephrology Unit, Careggi University Hospital, Florence, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        12
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Denmark
      </country>
      <medlineta>
       Transpl Infect Dis
      </medlineta>
      <nlmuniqueid>
       100883688
      </nlmuniqueid>
      <issnlinking>
       1398-2273
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       drug-drug interaction
      </keyword>
      <keyword majortopicyn="N">
       kidney transplant
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32279418
      </articleid>
      <articleid idtype="doi">
       10.1111/tid.13286
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32277836
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Electronic">
        1424-3997
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         150
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Swiss medical weekly
       </title>
       <isoabbreviation>
        Swiss Med Wkly
       </isoabbreviation>
      </journal>
      <articletitle>
       Benign COVID-19 in an immunocompromised cancer patient -Â  the case of a married couple.
      </articletitle>
      <pagination>
       <medlinepgn>
        w20246
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.4414/smw.2020.20246
      </elocationid>
      <elocationid eidtype="pii" validyn="Y">
       Swiss Med Wkly. 2020;150:w20246
      </elocationid>
      <abstract>
       <abstracttext>
        Respiratory failure in COVID-19 is a common feature in fatal cases and has been considered as a failure of the immune system to control the virus. Here we report the case of COVID-19 affecting an immunocompromised women and her presumably immunocompetent spouse. A married couple (age 60 years) was simultaneously admitted to the emergency department on 10 March 2020 because of dyspnoea and fever, consistent with COVID-19. The wife (patient 1) was partially immunocompromised as a consequence of a recently started chemotherapy with fulvestrant and abemaciclid for recurring breast cancer, her husband (patient 2) had been healthy except for a history of controlled arterial hypertension. Both patients were treated with darunavir/cobicistat and hydroxychloroquine. The clinical course of the immunocompromised partner was benign, without need of intensive care. She was able to leave the hospital on day 6 after admission. In contrast, her husband needed intensive care and his recovery was slow, although eventually successful too. These findings suggest that the course of COVID-19 is not necessarily ominous in the presence of a compromised immune response and tend to reinforce the emerging therapeutic concepts of a controlled mitigation of the immune cascade following SARS CoV-2 infection.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Spezzani
        </lastname>
        <forename>
         Valentina
        </forename>
        <initials>
         V
        </initials>
        <affiliationinfo>
         <affiliation>
          Family Medicine, UnitÃ  Sanitaria Locale del Servizio Sanitario Regionale Emilia-Romagna, Modena, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Piunno
        </lastname>
        <forename>
         Alessio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Radiology, Ospedale di Sassuolo (Prov. Modena), Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Iselin
        </lastname>
        <forename>
         Hans-Ulrich
        </forename>
        <initials>
         HU
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant for Interprofessional Communication, Riehen, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D002363">
        Case Reports
       </publicationtype>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        11
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Swiss Med Wkly
      </medlineta>
      <nlmuniqueid>
       100970884
      </nlmuniqueid>
      <issnlinking>
       0036-7672
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000900">
        Anti-Bacterial Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        4QWG6N8QKH
       </registrynumber>
       <nameofsubstance ui="D006886">
        Hydroxychloroquine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        LW2E03M5PG
       </registrynumber>
       <nameofsubstance ui="D000069547">
        Cobicistat
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        YO603Y8113
       </registrynumber>
       <nameofsubstance ui="D000069454">
        Darunavir
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000900">
        Anti-Bacterial Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D001943">
        Breast Neoplasms
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000150">
        complications
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000069547">
        Cobicistat
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003422">
        Critical Care
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000069454">
        Darunavir
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004417">
        Dyspnea
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004636">
        Emergency Service, Hospital
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005260">
        Female
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005334">
        Fever
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006886">
        Hydroxychloroquine
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007121">
        Immunocompetence
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016867">
        Immunocompromised Host
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008297">
        Male
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008875">
        Middle Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D009364">
        Neoplasm Recurrence, Local
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018454">
        Spouses
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016896">
        Treatment Outcome
       </descriptorname>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277836
      </articleid>
      <articleid idtype="doi">
       10.4414/smw.2020.20246
      </articleid>
      <articleid idtype="pii">
       Swiss Med Wkly. 2020;150:w20246
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277367
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1434-9949
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical rheumatology
       </title>
       <isoabbreviation>
        Clin. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s10067-020-05073-9
      </elocationid>
      <abstract>
       <abstracttext>
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such asÂ air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such asÂ arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Pointsâ¢ Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.â¢ Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.â¢ Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5035-7396
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. durgapmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agarwal
        </lastname>
        <forename>
         Vikas
        </forename>
        <initials>
         V
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4508-1233
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gasparyan
        </lastname>
        <forename>
         Armen Yuri
        </forename>
        <initials>
         AY
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8749-6018
        </identifier>
        <affiliationinfo>
         <affiliation>
          Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zimba
        </lastname>
        <forename>
         Olena
        </forename>
        <initials>
         O
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4188-8486
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Rheumatol
      </medlineta>
      <nlmuniqueid>
       8211469
      </nlmuniqueid>
      <issnlinking>
       0770-3198
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Epidemiology
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hypothesis
      </keyword>
      <keyword majortopicyn="N">
       Immunity
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       Vaccines
      </keyword>
      <keyword majortopicyn="N">
       Vitamin D
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277367
      </articleid>
      <articleid idtype="doi">
       10.1007/s10067-020-05073-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s10067-020-05073-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>